Vol. 1 Issue 11    Friday, December 7, 2007

 Commercial Scale


 Erythromycin base
 Erythromycin estolate
 Erythromycin ethylsuccinate
 Erythromycin oxime  (intermediate)
 Erythromycin phosphate
 Erythromycin propionate
 Erythromycin stearate

 Lisinopril dihydrate
 Losartan potassium

 Sodium valproate
 Valproic acid

 Alendronate sodium
 Zoledronic acid

 Sedative, Hypnotic

 Venlafaxine hydrochloride

 Cetirizine dihydrochloride

 Clopidogrel bisulphate

 Pilot Plant Scale
 Pioglitazone hydrochloride
 Rosiglitazone maleate

 R & D Scale

 Pamidronate disodium
 Perindopril erbumine
 Zolpidem tartrate

 Benazepril hydrochloride
 Risedronic acid

      Product under patent  offered  only
      for exempted research, clinical and
      development  purposes. Only  non-
      infrining   products   and  processes
      are offered, subject to patent status
      verification by client.
  • Custom Syntheses  
  • Contract Manufacturing
  • FTE Research
  • Analytical Support   
  • Intermediates & APIs
  • Building Blocks     

New Committee of Administration at PHARMEXCIL

We  are  pleased  to  inform  that  in  the  3rd  Annual  General   Meeting  of  PHARMEXCIL, held  on  the  28th  November 2007,
Mr. Smitesh C Shah, Chairman &  Managing  Director of  Calyx Chemicals &  Pharmaceuticals Ltd., Mumbai has  been   elected Vice  Chairman  of  the  Council  and  Mr. Venkat  Jasti,  Managing  Director  of   Suven  Life  Sciences  Limited, Hyderabad  has been  elected  as the Chairman of the Council for the years 2007-08 and 2008-09.

Other elected members of the Council are as follows: read here

Calyx at CPhI India 2007, Mumbai

We received an  overwhelming response during the recent CPhI  India 2007  held
at  the  Bombay  Exhibition  Center   at Goregaon, Mumbai. We sincerely thank
all our customers, suppliers and visitors
who  took the time out in  meeting  with
us during 25 – 27 November, 2007.

Excerpts from the speech delivered by Mr. Smitesh Shah – CMD of Calyx, at the Inauguration ceremony of CPhI India 2007 on the 25th November 2007

India  has  long  been  known  for the  unity in  diversity. Today, the  world’s  largest democracy has  come to  the  forefront  as a
global resource for industry and services. Its pool of  technical  skill, its  base of  English  speaking  populace with  an increasing disposable income and its burgeoning market have all combined to enable India emerge a viable partner to Global industry.

Investment  opportunities  in  India  are  today  perhaps at  a  peak. Supported   by  India’s  natural  strengths, the  country  offers investment  opportunities  in  excess  of  US  500  billion in  diverse sectors  over the  next five years. The  government of  India is committed  to enabling  foreign  investors  discover  India  as a partner- with  whom  they  can  work  in synergy  to  achieve  their objectives of growth and profitability.

Welcome to India and CPhI.

Rich  and   resplendent  with  a   repertoire  of    knowledge   and   character, Dr. Venkateswarlu nurtures and tends the budding greens (Indian industry) as they bloom. He is our unshakable pillar the “Science Czar”.

About CPhI and its organizers.

There are several ingredients that go into a winning business including a great idea, a great team, great passion, and great leadership. All are important, but great  passion  can be  the fire  that  helps  fuel  the  success. They  are  our catalysts. Thanks to CMP and its team.
Read the full speech

Winners of Raffle

We had organized 2 raffles, one on the 25th November and second on the 26th November 2007 during the CPhI India 2007 event and are pleased to announce the winners.

CONGRATULATIONS !                   CONGRATULATIONS !                     CONGRATULATIONS !
 Mr. Suresh Kumar Mogra - Winner of the Digital Camera       Ms. Parisa Zandi - Winner of the Swarovski Crystal

 "The information in this e-mail and any attachments is confidential and may be legally privileged. It is intended solely for the addressee or addressees. If you are not an intended recipient, please delete the  message and any   attachments and notify the sender of  misdelivery. Any use or disclosure of  the  contents of either is unauthorized  and  may   be unlawful. All  liability  for viruses is excluded to the fullest   extent permitted by law. Any views   expressed in this message  are those of the individual sender, except where the sender   states them, with requisite authority, to be those of the specific Calyx company."
To unsubscribe from this Newsletter send blank email to pharmanews@calyxindia.com